Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Clinical trial NCT07115095 · COMPLETED

Trial details

NCT number: NCT07115095
Sponsor: Nanlin Li
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2021-01-01
Primary completion: 2023-01-01
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.